Semantic Scholar uses AI to extract papers important to this topic.
Thalidomide Teratogenicity Target In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for… Expand The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general population and increases further in cancer… Expand BACKGROUND
High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the… Expand Although thalidomide (Thal) was initially used to treat multiple myeloma (MM) because of its known antiangiogenic effects, the… Expand BACKGROUND
Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone… Expand Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans. We have demonstrated that orally administered… Expand We have examined the mechanism of thalidomide inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF… Expand Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are… Expand Sir,—Congenital abnormalities are present in approximately 1.5% of babies. In recent months I have observed that the incidence of… Expand